The content on this page is designed for Australia. Check courses designed for Canada (EN)
This course has expired. View available courses.
English
Targeted therapies for advanced/metastatic renal cell carcinoma (mRCC) – Royal Australasian College of Surgeons
DURATION
PROFESSION
Physician
# OF CREDITS
2
ACCREDITATION
EXPIRY DATE
2017-06-25
Learning objectives
After completing this module, participants will have an enhanced understanding of:
- the rapidly evolving landscape of advanced/metastatic renal cell carcinoma (mRCC) therapy, including review of:
- mechanisms of action of signal transduction inhibitors
- clinical trial evidence for standard of care treatment of different categories of advanced RCC patients
- indications, contra-indications, side effect profiles and current Pharmaceutical Benefits Scheme (PBS) listing of reimbursed targeted therapies for advanced/metastatic RCC
Cost of course:
Free